This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patie… (NCT05061940) | Clinical Trial Compass
TerminatedNot Applicable
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Stopped: Development program terminated
United States22 participantsStarted 2021-05-05
Plain-language summary
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be willing and able to provide written informed consent
* Age ≥ 18 years
* Histologically- or cytologically-confirmed, relapsed/refractory, and metastatic or locally advanced head and neck, cervical, melanoma or non-small cell lung cancers. Other solid tumor types may be analyzed at the discretion of the Sponsor
* Able to provide archived tumor tissue or have existing data on TAAs, HPV status or HLA sub-type
* Willing to provide a saliva sample
Exclusion Criteria:
* There are no exclusion criteria for this study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was terminated before completing — do you know why it was stopped, and does that affect whether the biomarker results from it are still considered reliable or useful for guiding my treatment?
2Since this screening protocol was looking at whether patients with my type of cancer expressed specific markers like TAA or HPV-16 E6/E7, is there a way to still get tested for those markers outside of this trial, and would those results matter for any other treatment options I might have?
3This study was checking suitability for something called 'Repertoire Immune Medicines treatment protocols' — are any of those actual treatment trials still open and enrolling, and would I potentially be a candidate worth evaluating for them?
4Given that this was a Phase NA screening study rather than a treatment trial, what do the results or data collected so far actually tell us — and is there any other active study that's testing the therapies this screening was designed to feed into?
5Since my diagnosis involves one of the cancer types this trial was focused on — like HPV-related cancer or melanoma — should we proactively check my HPV-16 or HLA status anyway, since that information might open or close doors to other immunotherapy options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency of subjects with the expression of multiple tumor associated antigens and/or HPV-16 E6/E7.